PEB: Pacific Edge Diagnostics

Thanks Yelk for that, I’ve been a hesitant guest here for a while but a bit hesitant to post.

You know how it goes, 10 years of molecular DNA stuff in the lab, then 2-3 years on clinical trials and approvals, then they get to a point where it becomes all about coverage and sales traction, a sweet spot for me as an investor despite a slightly higher market cap at that stage. I prefer that as an entry point rather than waiting for years of lab time to go by, you know.

Seems to me that pacific edge diagnostics are tracking along a similar sequence to EXAS, perhaps 18 months behind. Sixth most common cancer vs fourth most common, different target markets and relative sizes though, specialist urologist’s vs oncologists and family practitioners.

I’ve accumulated a few and noted last week that three of the larger shareholders are presently doing the same thing.

Does anyone else share a common interest in this company, for comparing notes ?